- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06240767
Clinical Study on the Treatment of Advanced Recurrent Tumors With Anticancer Mouse Characteristic Human Neutrophils
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Peihua Lu, Doctor
- Phone Number: 13621500031
- Email: 13625653@qq.com
Study Locations
-
-
Jiangsu
-
Wuxi, Jiangsu, China, 214043
- Recruiting
- Wuxi People's Hospital
-
Contact:
- Peihua Lu, MD
- Phone Number: +86 13621500031
- Email: 13625653@qq.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 18 ~ 75 years old (inclusive), gender is not limited
- Malignant tumor confirmed by puncture pathology/postoperative pathology, or PET-CT multi-focal high signal, clinical stage IV
- Physical status score of 0-2 in ECOG scale
- Expected survival time ≥3 months
- Have measurable lesions, calculate the sum of the longest diameter of all target lesions, and report as the baseline sum diameter: the lesions can be accurately measured in at least one direction (record the longest diameter), as long as it conforms to RECIST1.1; If there are multiple lesions, a maximum of 5 lesions (no more than 2 per organ) are required; The efficacy of hematological malignancies such as leukemia can be confirmed by cytology/histology
- more than 4 weeks have elapsed since previous drug therapy, radiation therapy and surgery; Oral fluorouracil and small molecule targeted drugs required for more than 2 weeks or within 5 half-lives of the drug (whichever is longer)
- Laboratory tests meet the following criteria: (1) Bone marrow function: absolute count of blood neutrophils (ANC) ≥1*10^9/L, platelets (PLT) ≥75*10^9/L; (2) Liver function: serum total bilirubin (STB), bound bilirubin (CB) ≤ upper limit of normal (ULN) *1.5, alanine aminotransferase (ALT), aspartate aminotransferase (AST) ≤ULN*2.5 (in the absence of liver metastasis), or ≤ULN*5 (in the presence of liver metastasis); (3) Kidney function: serum creatinine (Cr) ≤ULN*1.5, endogenous creatinine clearance (Ccr) ≥50 mL/min (calculated by Cockcroft-Gault formula)
- Anti-neutrophil antibody test results are negative
- The patient volunteered and signed the informed consent
Exclusion Criteria:
1: Uncontrolled or severe cardiovascular disease, diabetes, major heart disease, such as arrhythmia within 30 days, congestive heart failure, or severe coronary artery disease
2: HIV infection, no recent (within 30 days) use of immunosuppressive drugs other than steroids
3: Pregnant and lactating women
4: Previous history of stem cell and organ transplantation
5: Patients who have been using or are using immunosuppressants for a long time
6: Symptomatic brain metastases are not controlled
7: People who are known to be severely allergic to granulocyte infusion (or test positive for anti-neutrophil antibodies)
8: People with coagulation disorders
9: Mental disorders are not under control
10: Patients with severe autoimmune diseases
11: Cases deemed unsuitable for inclusion by the investigator
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Clinical study of human granulocyte in the treatment of advanced recurrent tumor
Experimental: Anticancer mouse characteristic human granulocyte treatment of advanced recurrent tumors. A single infusion of human granulocytes with anti-cancer mouse characteristics was performed for 5 consecutive transfusions at a interval of 2±1 day, and the safety and efficacy were clinically observed. |
The number of single granulocytes per infusion was 2.0-5.0×10^10, with an interval of 2±1 day and 5 continuous infusions.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical efficacy evaluation
Time Frame: 6 months after treatment
|
Target lesions were assessed according to RECIST1.1 criteria.
All other lesions, including small lesions (lesions with a maximum diameter of less than 20mm measured by conventional methods or less than 10mm measured by spiral CT scanning, or less than 15mm measured when the CT layer thickness is 5mm) and true unmeasurable lesions are not required to be measured, described as "with" or "without".
|
6 months after treatment
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- WX03-02B0205-072100-62
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Cancer
-
STORM Therapeutics LTDRecruitingCancer | Advanced Solid Tumor | Advanced CancerUnited States
-
Merck Sharp & Dohme LLCCompletedAdvanced Cancer Relapsed | Advanced Cancer Refractory
-
BiOneCure Therapeutics Inc.RecruitingCancer | Advanced Solid Tumor | Advanced Cancer | OncologyUnited States
-
Teon Therapeutics, Inc.Merck Sharp & Dohme LLCTerminatedCancer | Advanced Solid Tumor | Advanced Cancer | OncologyUnited States
-
Zhejiang UniversityRecruitingAdvanced Colorectal Cancer | Advanced Hepatocellular Carcinoma | Advanced Gastric Cancer | Advanced Pancreatic CancerChina
-
PfizerTerminatedAdvanced Solid Tumors | Advanced CancerUnited States
-
AVEO Pharmaceuticals, Inc.CompletedAdvanced Cancer | Refractory CancerUnited States
-
Avera McKennan Hospital & University Health CenterCompleted
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
University Health Network, TorontoUniversity of UlmRecruiting
Clinical Trials on Granulocyte infusion
-
Qianfoshan HospitalChinese Medical AssociationRecruiting
-
Kahramanmaras Sutcu Imam UniversityÖzlem Güler; Filiz Alkan BaylanCompleted
-
Amira Magdi Guergues SelimUnknownEndometriosis | Recurrent Implantation Failure
-
Beth Israel Deaconess Medical CenterNational Cancer Institute (NCI); Dana-Farber Cancer InstituteCompletedRenal CancerUnited States
-
Terumo BCTCompletedGranulocyte/ Polymorphonuclear CellsUnited States
-
Lei LiRecruitingFebrile Neutropenia | Epithelial Ovarian Cancer | Adverse Event | Cost-effectiveness | Myelosuppression Adult | Colony Stimulating FactorsChina
-
The University of Texas Health Science Center,...United States Department of Defense; U.S. Army Medical Research and Development...Active, not recruitingTBI (Traumatic Brain Injury) | Brain Injuries, Traumatic | Brain Injuries, AcuteUnited States
-
Jianming TanUnknownOsteochondritis of the Femoral HeadChina
-
Boston Medical CenterTerminatedAL AmyloidosisUnited States
-
Bispebjerg HospitalPsychiatric Centre RigshospitaletCompletedCognitive Change | Type2 Diabetes | KetonemiaDenmark